Next-Level Compliance: What Every Board Member Should Know

October 2016

Abstract

This article is geared towards members of Boards of Directors, C-level company leadership, and compliance professionals who recognize the need to continually improve compliance. Why is it important to drive compliance performance to the next level? It is vital, because status quo performance in a rapidly evolving global environment earns a failing mark. If your company is not adapting, if it does not have ethical leaders in the right places setting the right ethical “tone at the top,” the compliance program is not as robust as it should be and the company is likely carrying more compliance-related risk than it should.

Author

Fabiana Lacerca-Allen

Chief Compliance Officer, Cipla, USA

M. Fabiana Lacerca-Allen is a senior compliance and legal executive with over 30 years of experience leading global compliance, legal, and governance programs across the pharmaceutical, biotechnology, and technology sectors. She currently serves as Chief Compliance Officer for Cipla USA and has held senior leadership roles at Aimmune Therapeutics, Elan Pharmaceuticals, Mylan, Bristol-Myers Squibb, Microsoft, Merck, and AT&T. She brings deep expertise in risk-based compliance program design aligned with DOJ and OIG expectations, including third-party risk management, global investigations, data integrity, ethical culture transformation, and crisis preparedness. She regularly advises boards and executive leadership teams on international operations and enterprise governance. Fabiana serves as a Board Director and Audit Committee Member of Shield Therapeutics and holds a risk and governance advisory position with the International Federation of Red Cross and Red Crescent Societies (IFRC). She is also Adjunct Professor at Fordham University School of Law, teaching compliance, ethics, and governance. She is author of Crisis Capable and a frequent international speaker. She previously served as Chair of the Bay Area Ethics & Compliance Association and Co-Chair for CBI (Advanstar). She holds a JD and LLM and conducted academic research in international environmental law through the Gioja Research Institute.

Company

Cipla

Cipla Limited is a leading Indian multinational pharmaceutical company, founded in 1935, focused on developing high-quality, affordable medicines across various therapeutic areas, including respiratory, cardiovascular, and HIV/AIDS. With 46 global manufacturing sites, it produces 1,500+ products and operates in 80+ countries.

As more and more companies have made big compliance mistakes and have been caught by governmental authorities, pundits have been attributing these miscues to company culture. These incidents include the...Read more

David Birk

Managing Director, Black Belt Compliance, LLC, USA

Role of In-House Counsel in Transnational Operations

A fundamental role of in-house legal counsel is to assist the operations teams in identifying, assessing and tailoring their procedures to ensure compliance with applicable requirements and to address the...Read more

Philip Kessack

Vice President and Senior Legal Counsel, AECOM Technology Corporation, USA

Introducing, Implementing and Improving Compliance; Challenges in Cross Boarder Environment and Market Entry Situations

During previous years, the M&A transaction field has been less active. Nevertheless the market is starting to merge again and transactions are appearing on the desks of in-house counsels. In...Read more

Diana Maher

Senior Legal Counsel, Kone Corporation, Finland

Implementing Effective Compliance Programs in Jurisdictions Where the Rule of Law is Weak

Multinational organizations increasingly operate in jurisdictions where the rule of law is weak, inconsistently enforced, or subject to political and economic influence. For pharmaceutical and biotechnology companies, these environments present...Read more